MEX3A: A Non-Code RNA Molecule with Potential Drug Target and Biomarker Properties

Target Name: MEX3A

NCBI ID: G92312

MEX3A

MEX3A: A Non-Code RNA Molecule with Potential Drug Target and Biomarker Properties

MEX3A (RNF162) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and biology have made it an attractive target for researchers to study, and recent studies have shed new light on its role in disease progression and treatment.

MEX3A is a RNA molecule that is found in various tissues throughout the body, including the brain, heart, and kidneys. It is composed of 74 amino acid residues and has a unique structure that consists of a long terminal extension, which is known as a \"T-loop,\" and a stem-like region. The T-loop is the region where MEX3A interacts with other molecules, including proteins, and is thought to play a key role in this interaction.

One of the key features of MEX3A is its ability to interact with a variety of proteins, including casein kinase (CK) 3. CK3 is a protein that is involved in many cellular processes, including cell signaling, DNA replication, and metabolism. MEX3A has has been shown to interact with CK3 and can modulate its activity, which may have implications for the regulation of cellular processes.

In addition to its interaction with CK3, MEX3A has also been shown to interact with several other proteins, including the protein kinase B-3 (BK-3). BK-3 is a protein that is involved in cell signaling and metabolism, and MEX3A has been shown to regulate its activity, which may have implications for the regulation of cellular processes.

MEX3A has also been shown to play a role in the regulation of gene expression. Researchers have identified a variety of genes that are regulated by MEX3A, and they have shown that MEX3A can either activate or repress the expression of these genes, depending on the context. This regulation of gene expression is important for the development and progression of diseases, as it allows cells to respond to various stimuli and to maintain their integrity.

In addition to its role in gene expression, MEX3A has also been shown to play a role in the regulation of cellular signaling pathways. Researchers have identified a variety of signaling pathways that are regulated by MEX3A, including the T-cell signaling pathway. This pathway is important for the development and regulation of T-cells, which play a key role in immune surveillance and disease resistance.

MEX3A has also been shown to be involved in the regulation of cellular processes related to inflammation and fibrosis. In diseases such as cancer and autoimmune disorders, inflammation and fibrosis can be harmful and contribute to the development and progression of these diseases. MEX3A has also been shown to play a role in regulating these processes and may have implications for the development and treatment of these diseases.

In conclusion, MEX3A is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases. Its unique structure and biology, as well as its ability to interact with a variety of proteins, including casein kinase (CK ) 3 and the protein kinase B-3, make it an attractive target for researchers to study. Further studies have shown that MEX3A is involved in the regulation of gene expression, cellular signaling pathways, and cellular processes related to inflammation and fibrosis. These findings suggest that MEX3A may have implications for the development and treatment of various diseases. Further research is needed to fully understand its role and to identify its potential drug targets.

Protein Name: Mex-3 RNA Binding Family Member A

Functions: RNA binding protein, may be involved in post-transcriptional regulatory mechanisms

The "MEX3A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MEX3A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets